What is Jude Bio?
Jude Bio is a biotechnology innovator pioneering the development of oligonucleotide medicines specifically engineered for kidney-targeted delivery. At the core of its operations is the proprietary STRIKE (Selectively Targeting RNA Into KidnEy) platform. This technology leverages natural, endogenous mechanisms to facilitate the precise uptake of ligand-siRNA conjugates by specific renal cell types. By enabling targeted gene silencing of disease-modifying genes, Jude Bio is addressing critical unmet needs in both systemic and renal-specific pathologies. The company's market position is defined by its ability to bridge the gap between complex RNA science and practical, organ-specific therapeutic applications, positioning it as a key player in the next generation of precision medicine.
How much funding has Jude Bio raised?
Jude Bio has raised a total of $100M across 1 funding round:
Angel/Seed
$100M
Angel/Seed (2024): $100M with participation from The Column Group, Atlas Venture, and TCG
Key Investors in Jude Bio
The Column Group
The Column Group is a venture ecosystem focused on advancing scientific innovation in the life sciences sector, providing comprehensive support from inception to exit.
Atlas Venture
Atlas Venture is a pioneering early-stage venture capital firm focused on building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines.
TCG
TCG Inc delivers specialized information technology and management advisory services, with a specific practice area in health science analytics and federal health program support.
What's next for Jude Bio?
With this major enterprise-level funding, Jude Bio is well-positioned to scale its research and development operations. The immediate strategic focus will likely involve advancing its lead drug programs through preclinical validation and toward initial human trials. By utilizing the STRIKE platform to refine its ligand-siRNA conjugate portfolio, the company aims to establish a robust clinical footprint in the nephrology space. Future growth will depend on the successful translation of its gene-silencing capabilities into durable therapeutic outcomes, potentially attracting further partnerships or strategic acquisitions as the platform matures. The company remains committed to optimizing its delivery mechanisms to ensure that its RNA-based interventions can effectively treat chronic kidney conditions that have historically been difficult to manage with conventional pharmacology.
See full Jude Bio company page
